Drugs / MAP4343
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03870776 | Jun 2019 → Nov 2024 | depressive disorder | Mapreg | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04157114 Comparator | Dec 2021 → Dec 2022 | alcohol-related disorders | The Scripps Research Institute | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAP4343 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03870776 ↗ |
| Route | Oral | “Daily oral administration of MAP4343” NCT03870776 ↗ |